Subtype
Prostate Adenocarcinoma
CI-CAN-00003766PRADExplore in graph →
133 active trials1 approved drugs3 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003766PRADExplore in graph →
Clinical trials
433 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (71)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 |
| clinicaltrials |
| NCT03404648 | Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI | completed | Phase 3 | 19 | Mayo ClinicOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02175212 | Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer(AADLPC) | completed | Phase 3 | 362 | Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03780023 | CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients | completed | — | 5 | University of California, DavisOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02472275 | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | completed | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02228265 | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | completed | — | 41 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03504995 | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer. | completed | N/A | 10 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01664130 | High-Dose Stereotactic Radiation for Prostate Cancer | completed | N/A | 35 | Case Comprehensive Cancer CenterOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT02470910 | Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03077659 | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | completed | Phase 2 | 16 | NanOlogy, LLCINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01028885 | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01117935 | Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer | completed | N/A | 55 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03034070 | Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer.(TFE-TVE) | completed | N/A | 30 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 10, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | completed | Phase 2 | 300 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT00570700 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | completed | Phase 2 | 38 | University of California, IrvineOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01731912 | Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer | completed | N/A | 16 | University of WashingtonOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT01992016 | A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine | completed | N/A | 11 | University of Colorado, DenverOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT02234921 | Pilot Study of DRibble Vaccine for Prostate Cancer Patients(DRibble) | completed | Phase 1 | 3 | UbiVacINDUSTRY | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01270880 | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01519414 | Tivantinib in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01656304 | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 16 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT00520481 | Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2018 | clinicaltrials |
| NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00165399 | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | completed | Phase 2 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT02532114 | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | completed | Phase 1 | 5 | University of WashingtonOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 211 | National Cancer Institute (NCI)NIH | 2 | Feb 26, 2018 | clinicaltrials |
| NCT02025361 | Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy | completed | Phase 4 | 422 | Bagcilar Training and Research HospitalOTHER_GOV | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01949519 | Docetaxel and Lycopene in Metastatic Prostate Cancer | completed | Phase 1 | 24 | Medical University of South CarolinaOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01433913 | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02342626 | Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer | completed | N/A | 140 | University of RochesterOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00466752 | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | completed | Phase 2 | 5 | University of WashingtonOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT00589472 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer(TARGET) | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00243321 | High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer | completed | N/A | 27 | Virginia Commonwealth UniversityOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01023061 | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer(RAD1) | completed | Phase 2 | 24 | University of WashingtonOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01050842 | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Mar 23, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Apr 23, 2021source: clinicaltrials